Peer-reviewed veterinary case report
Lokivetmab treatment for itching in dogs with allergic dermatitis
By Van Brussel, Leen et al.·Published in Veterinary dermatology·2021·Zoetis Belgium SA·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
- Species:
- dog
Plain-English summary
A group of dogs with allergic dermatitis, which causes severe itching, were treated with lokivetmab, a new medication designed to reduce itching, or a saline placebo. Owners reported a significant decrease in their dogs' itching within just a day of starting treatment, and by the end of the study, the lokivetmab group showed a much greater improvement compared to the placebo group. Both treatments had similar safety profiles, meaning lokivetmab was well-tolerated. Overall, lokivetmab proved to be an effective and safe option for managing itching in dogs with allergic dermatitis.
People also search for: dog itching treatment · lokivetmab for allergic dermatitis · how to help my dog with skin allergies
Abstract
BACKGROUND: Interleukin (IL)-31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. HYPOTHESIS/OBJECTIVES: To demonstrate the efficacy and safety of lokivetmab (canine anti-IL-31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs. ANIMALS: Dogs that were at least moderately pruritic with a presumptive diagnosis of allergic dermatitis were enrolled in Portugal, Hungary, France and Germany by 12 primary care practitioners and two veterinary dermatology referral specialists. METHODS AND MATERIALS: Dogs were randomised to receive either placebo (saline) or lokivetmab (1.0-3.3 mg/kg) by subcutaneous injection on Day (D)0. Owners evaluated pruritus using a validated Visual Analog Scale (pVAS) daily until D7 and then weekly until D28. The severity of dermatitis was assessed by the investigators using a modified VAS on D0, D7, D14 and D28. RESULTS: Beginning at D1, owner-assessed pVAS least square means were significantly reduced in the treatment group versus the placebo group (57.7% versus 21.8% reduction on D28). For all time points, investigator-assessed VAS means were significantly reduced in the lokivetmab group versus the placebo group (57.1% versus 20.5% reduction on D28). Overall, the occurrence of adverse health events during the evaluation period was comparable between the two groups. CONCLUSIONS AND CLINICAL IMPORTANCE: Lokivetmab is a safe and efficacious treatment for dogs with allergic dermatitis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34180084/